NovoLog (insulin aspart) / Novo Nordisk - LARVOL DELTA

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=85 | Terminated | Sponsor: Emory University | N=255 ➔ 85 | Active, not recruiting ➔ Terminated; The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.

Enrollment change • Trial termination • Diabetes • Metabolic Disorders

Case Report: Case analysis of a juvenile type 1 diabetes mellitus patient with Mauriac syndrome. (PubMed, Front Endocrinol (Lausanne)) - "Her regimen includes NovoRapid before meals and glargine at bedtime, but she has irregular meal patterns, inconsistent blood glucose monitoring, and poor insulin adherence...An insulin pump was subsequently used for continuous subcutaneous insulin infusion (with Gansulin R before meals)...Liver function and lipids were mostly normal at discharge. Two months later, she was readmitted for DKA; liver function was normal, but hepatomegaly with tenderness persisted."

Journal • Diabetes • Genetic Disorders • Hematological Disorders • Hepatology • Metabolic Disorders • Pain • Type 1 Diabetes Mellitus

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (clinicaltrials.gov) - P2/3 | N=62 | Completed | Sponsor: Amphastar Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

DREAMS-3: A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity (clinicaltrials.gov) - P3 | N=349 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Refractory Diabetic Ketoacidosis: A Rare Case of Exogenous Insulin Antibody Syndrome (ENDO 2026) - "His diabetes was well-controlled (A1c 6.6%) on liraglutide and 70/30 insulin 10 units twice a day...Switching to Lantus and Novolog did not improve glycemic control...Mycophenolate mofetil (MMF) was started on day 15, and methylprednisolone dose was decreased to 0.6 mg/kg to reduce steroid-induced hyperglycemia. Since he still required around 200 units of insulin daily, intravenous immunoglobulin (IVIG) 500 mg/kg was administered on day 20 with plans for rituximab while inpatient...Management of EIAS can be challenging as there is no established treatment algorithm for this condition. Utilization of multiple treatment modalities targeting antibody clearance and immunosuppression may be required as exemplified by this case."

Clinical • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Comparison of the Pharmacokinetics （PK）and Pharmacodynamics （PD）Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers (clinicaltrials.gov) - P=N/A | N=44 | Recruiting | Sponsor: Zhuhai United Laboratories Co., Ltd.

New trial

BUDGET IMPACT ANALYSIS OF KIRSTY AND MERILOG IN THE TREATMENT OF DIABETES MELLITUS FROM A U.S. PAYER PERSPECTIVE (ISPOR 2026) - "The estimated three-year plan costs for NovoLog multi-dose vials and prefilled pens in the "without" scenario were $134,429,460 and $173,082,111, respectively... The inclusion of biosimilars Kirsty and Merilog to the plan formulary yields savings over three years for both multi-dose vials and prefilled pens."

HEOR • Diabetes • Metabolic Disorders

COST-EFFICIENCY AND EXPANDED-ACCESS OF KIRSTY/MERILOG VS NOVOLOG IN DIABETES MELLITUS (ISPOR 2026) - "Kirsty/Merilog multi-dose vials and prefilled pens represent cost-efficient alternatives to Novolog. Conversion can generate substantial savings that may be reinvested to expand patient access on a budget-neutral basis."

Diabetes • Metabolic Disorders

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Amphastar Pharmaceuticals, Inc.

New P2/3 trial

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Recruiting ➔ Completed | N=20 ➔ 11

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor (clinicaltrials.gov) - P=N/A | N=44 | Completed | Sponsor: Aristotle University Of Thessaloniki | Unknown status ➔ Completed | N=25 ➔ 44

Enrollment change • Real-world evidence • Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=255 | Active, not recruiting | Sponsor: Emory University | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (clinicaltrials.gov) - P=N/A | N=218 | Completed | Sponsor: Beijing Hospital | Not yet recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2023 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (clinicaltrials.gov) - P4 | N=76 | Completed | Sponsor: Medical University of Warsaw | Not yet recruiting ➔ Completed | Trial completion date: Aug 2023 ➔ Dec 2024

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

In brief: Kirsty - an insulin aspart interchangeable with NovoLog. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

NIVOLUMAB-INDUCED DKA IN A PREVIOUS NONDIABETIC (CHEST 2025) - "Patient subsequently was discharged home with Lantus and NovoLog. With the increasing use of Checkpoint inhibitors in malignancies, practitioners should be aware of potentially serious complications including DKA and worsening glycemic control. Monitoring blood glucose and HbA1C levels before and after initiation of an immune checkpoint inhibitor should be discussed with patients prior to initiating therapy, in order to help monitor for potentially serious complications."

Hypertension • Melanoma • Metabolic Disorders • Solid Tumor • Type 2 Diabetes Mellitus

HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - P=N/A | N=150 | Active, not recruiting | Sponsor: Weill Cornell Medical College in Qatar | Trial completion date: Oct 2024 ➔ Oct 2026

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Emory University | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders

Preserved C-peptide Five Years After LADA Diagnosis: Focus On Prandial Glycaemic Control (ENDO 2025) - "She was started on sc Novorapid 3-6 units 15 mins premeal at 1 unit to 10-gram carbs, and PO linagliptin 5 mg om. Empagliflozin and metformin were discontinued...However, the use of DPP4-inhibitors has been found useful. CONCLUSION RCTs utilizing C-peptide and CGM to inform the best regimens of insulin and/or OHA treatment for C-peptide preservation in LADA patients are needed."

Diabetes • Hypoglycemia • Immunology • Metabolic Disorders

Navigating the Uncertainty: Atypical Diabetes Mellitus with Negative Biomarkers and Complex Management (ENDO 2025) - "He was discharged with insulin (Lantus 8 units and Novolog 2 units TID) and metformin (METF) 1000 mg BID.Two weeks later when he was evaluated in clinic he was only taking METF with small doses of short-acting insulin, as needed...Patient was trialed with acarbose with no effect on BG, then a dipeptidyl peptidase-4 (DDP-4) inhibitor... This case highlights the complexity involved in diagnosing and managing atypical forms of DM, including LADA, monogenic, and ketosis-prone DM. It is a spectrum, which may present with features of both type 1 and type 2 DM but lacks definitive biomarkers. Clinicians should consider the atypical forms in adult patients with new-onset diabetes and atypical presentations, especially when there is an absence of typical autoimmune markers."

Biomarker • Diabetes • Diabetic Retinopathy • Fatigue • Hypoglycemia • Immunology • Metabolic Disorders • Renal Disease • Retinal Disorders • Type 1 Diabetes Mellitus

Unraveling The Diagnosis: A Case Of HNF1A-MODY Misclassified As Type 1 Diabetes (ENDO 2025) - "He was overweight at diagnosis, started on metformin, then transitioned to insulin due to poor glycemic control...His regimen was adjusted to include Lantus, Novolog, and Trulicity, improving HbA1c to 7.9%...He was transitioned to glipizide, pioglitazone, and Trulicity, achieving an HbA1c of 6.9%.This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories...This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories. Misclassification as T1DM led to years of ineffective insulin therapy. A comprehensive evaluation, including C-peptide, antibody testing, and genetic analysis, enabled correct diagnosis and optimized therapy."

Clinical • Late-breaking abstract • Diabetes • Endocrine Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • HNF1A